GDRX Stock Price, GoodRx Holdings Inc Quote, Chart

Market Summary

USD6.96-0.01

Market Closed

-0.14%

GDRX Stock Price

View Fullscreen

GDRX RSI Chart

GDRX Valuation

Market Cap

2.9B

Price/Earnings (Trailing)

-322.5

Price/Sales (Trailing)

3.81

EV/EBITDA

26.05

Price/Free Cashflow

20.84

GDRX Price/Sales (Trailing)

GDRX Profitability

EBT Margin

-7.41%

Return on Equity

-1.16%

Return on Assets

-0.56%

Free Cashflow Yield

4.8%

GDRX Fundamentals

GDRX Revenue

Revenue (TTM)

750.3M

Rev. Growth (Yr)

6.81%

Rev. Growth (Qtr)

9.27%

GDRX Earnings

Earnings (TTM)

-8.9M

Earnings Growth (Yr)

-1.2K%

Earnings Growth (Qtr)

32.8%

Breaking Down GDRX Revenue

Last 7 days

6.9%

Last 30 days

5.9%

Last 90 days

4.0%

Trailing 12 Months

23.1%

How does GDRX drawdown profile look like?

GDRX Financial Health

Current Ratio

7.12

Debt/Equity

0.85

Debt/Cashflow

0.21

GDRX Investor Care

Buy Backs (1Y)

0.62%

Diluted EPS (TTM)

-0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	747.2M	745.1M	737.7M	750.3M
2022	788.3M	803.5M	795.7M	766.6M
2021	577.7M	631.1M	685.7M	745.4M
2020	428.8M	469.5M	510.1M	550.7M
2019	0	0	318.9M	388.2M
2018	0	0	0	249.5M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of GoodRx Holdings Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	nabiey romin	acquired	-	-	2,606	chief accounting officer
Apr 15, 2024	nabiey romin	sold (taxes)	-6,351	6.83	-930	chief accounting officer
Mar 08, 2024	voermann karsten	acquired	-	-	54,064	chief financial officer
Mar 08, 2024	nabiey romin	sold (taxes)	-28,237	7.54	-3,745	chief accounting officer
Mar 08, 2024	nabiey romin	acquired	-	-	10,201	chief accounting officer
Mar 08, 2024	voermann karsten	sold (taxes)	-129,990	7.54	-17,240	chief financial officer
Mar 06, 2024	spectrum equity vii, l.p.	back to issuer	-44,745,400	7.19	-6,223,280	-
Mar 06, 2024	spectrum equity vii, l.p.	back to issuer	-76,595	7.19	-10,653	-
Mar 06, 2024	spectrum equity vii, l.p.	acquired	-	-	6,223,280	-
Mar 06, 2024	francisco partners iv, l.p.	back to issuer	-35,102,400	7.19	-4,882,110	-

Which funds bought or sold GDRX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	Global Retirement Partners, LLC	sold off	-100	-95.00	-	-%
Apr 22, 2024	Rosenberg Matthew Hamilton	sold off	-100	-6,700	-	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	added	265	549,691	741,311	-%
Apr 22, 2024	GERBER, LLC	added	178	146,480	221,520	0.19%
Apr 19, 2024	Cutler Group LLC / CA	reduced	-91.74	-4,000	-	-%
Apr 18, 2024	WOLFF WIESE MAGANA LLC	sold off	-100	-3,015	-	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	-	-%
Apr 18, 2024	SJS Investment Consulting Inc.	reduced	-14.29	-4.00	43.00	-%
Apr 15, 2024	Counterpoint Mutual Funds LLC	reduced	-11.67	-16,832	246,278	0.06%
Apr 15, 2024	Future Financial Wealth Managment LLC	new	-	1,420	1,420	-%

Are Funds Buying or Selling GDRX?

Are funds buying GDRX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GDRX

No. of Funds

Unveiling GoodRx Holdings Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 08, 2024	francisco partners iv, l.p.	28.6%	46,680,496	SC 13D/A
Mar 08, 2024	spectrum equity vii, l.p.	24.2%	29,825,306	SC 13D/A
Feb 14, 2024	ameriprise financial inc	7.58%	7,001,503	SC 13G
Feb 13, 2024	vanguard group inc	9.07%	8,380,990	SC 13G/A
Feb 12, 2024	rubric capital management lp	6.36%	5,872,806	SC 13G
Jan 25, 2024	millennium management llc	0.7%	602,934	SC 13G/A
Nov 21, 2023	spectrum equity vii, l.p.	30.9%	36,048,589	SC 13D/A
Oct 27, 2023	hirsch douglas joseph	5.5%	5,120,852	SC 13D/A
Oct 27, 2023	bezdek trevor	5.5%	5,120,852	SC 13D/A
Aug 31, 2023	hirsch douglas joseph	9.8%	9,042,037	SC 13D

Recent SEC filings of GoodRx Holdings Inc

View All Filings

Date Filed	Form Type	Document
Apr 16, 2024	4	Insider Trading
Apr 05, 2024	S-3	S-3
Mar 19, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	8-K	Current Report
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading
Mar 08, 2024	4	Insider Trading

Peers (Alternatives to GoodRx Holdings Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	449.3B	371.6B	-0.74%	-0.51%	20.08	1.21	14.64%	11.24%
CI	103.0B	195.3B	0.26%	37.72%	19.17	0.53	8.17%	-20.79%
CVS	85.3B	357.8B	-12.72%	-6.73%	10.21	0.24	10.95%	93.52%
HCA	84.4B	65.0B	-3.19%	11.59%	16.11	1.3	7.86%	-7.11%
CNC	40.8B	154.0B	-1.43%	12.08%	15.09	0.26	6.54%	124.79%
DVA	11.6B	12.1B	-0.12%	51.97%	16.83	0.96	4.57%	23.40%
UHS	11.5B	14.3B	-8.62%	17.22%	16.03	0.81	6.59%	6.24%
MID-CAP
CHE	9.3B	2.3B	-4.84%	8.83%	34.2	4.12	6.06%	9.17%
ACHC	6.5B	2.9B	-7.52%	-4.24%	-301.31	2.23	12.20%	-107.93%
AMN	2.2B	3.8B	-10.62%	-35.16%	10.28	0.57	-27.73%	-52.50%
AMEH	2.1B	1.4B	-5.65%	-0.29%	34.21	1.5	21.19%	34.42%
SMALL-CAP
ADUS	1.5B	1.1B	-8.44%	-16.43%	24.6	1.45	11.31%	35.83%
BKD	1.3B	3.0B	7.61%	59.68%	-6.76	0.42	6.74%	20.73%
BEAT	53.7M	-	-3.27%	-3.72%	-3.67	-	-	-12.94%
AMS	19.0M	21.3M	13.26%	5.28%	35.63	0.89	8.00%	-62.25%

GoodRx Holdings Inc News

Latest updates

GoodRx Holdings Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Revenue	9.3%	197	180	190	184	184	187	192	203	213	195	177	160	154	140	123	133	118	102	-
Costs and Expenses	-1.5%	215	218	171	173	182	203	196	184	202	188	177	165	453	202	82.00	90.00	-	64.00	-
S&GA Expenses	2.3%	94.00	92.00	77.00	79.00	84.00	86.00	94.00	93.00	106	96.00	88.00	80.00	75.00	65.00	52.00	63.00	-	45.00	-
R&D Expenses	-19.1%	32.00	40.00	31.00	33.00	37.00	36.00	35.00	35.00	35.00	35.00	30.00	26.00	24.00	16.00	12.00	10.00	-	8.00	-
EBITDA Margin	9.5%	0.15*	0.13*	0.13*	0.09*	0.09*	0.08*	0.10*	0.10*	0.06*	-0.39*	-0.54*	-0.53*	-0.47*	0.14*	0.36*	0.34*	0.38*	0.24*	0.34*
Interest Expenses	0.7%	15.00	15.00	14.00	13.00	12.00	9.00	7.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	7.00	9.00	-	13.00	-
Income Taxes	115.2%	1.00	-8.11	-46.72	7.00	-2.77	19.00	-8.74	2.00	46.00	19.00	-37.30	-12.55	-7.36	-17.89	8.00	8.00	-	6.00	-
Earnings Before Taxes	47.1%	-24.63	-46.60	12.00	4.00	-4.74	-22.27	-10.16	14.00	6.00	1.00	-6.24	-10.89	-305	-67.93	35.00	35.00	-	25.00	-
EBT Margin	-53.1%	-0.07*	-0.05*	-0.02*	-0.04*	-0.03*	-0.02*	0.01*	0.02*	-0.01*	-0.47*	-0.62*	-0.60*	-0.55*	0.04*	0.24*	0.19*	0.21*	0.15*	0.21*
Net Income	32.8%	-25.87	-38.49	59.00	-3.29	-1.97	-41.73	-1.41	12.00	-39.91	-18.07	31.00	2.00	-298	-50.03	27.00	27.00	15.00	20.00	-
Net Income Margin	-158.0%	-0.01*	0.02*	0.02*	-0.06*	-0.04*	-0.09*	-0.06*	-0.02*	-0.03*	-0.41*	-0.50*	-0.55*	-0.53*	0.04*	0.19*	0.19*	0.17*	0.12*	0.18*
Free Cashflow	-74.3%	15.00	60.00	30.00	32.00	32.00	33.00	50.00	28.00	49.00	48.00	35.00	43.00	10.00	19.00	37.00	45.00	16.00	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-7.0%	1,589	1,708	1,692	1,612	1,605	1,567	1,592	1,538	1,608	1,614	1,587	1,511	1,470	1,547	387
Current Assets	-9.9%	873	969	919	907	920	878	894	995	1,089	1,052	1,076	1,123	1,086	1,181	87.00
Cash Equivalents	-15.4%	672	795	762	761	757	729	731	845	941	912	895	990	969	1,075	26.00
Net PPE	-5.6%	16.00	17.00	18.00	19.00	20.00	22.00	23.00	23.00	22.00	22.00	22.00	23.00	23.00	17.00	2.00
Goodwill	-0.3%	411	412	412	412	412	415	415	81.00	330	330	320	261	261	261	236
Liabilities	0.0%	827	827	797	784	790	779	774	752	776	768	763	762	759	790	737
Current Liabilities	4.0%	123	118	83.00	69.00	76.00	85.00	80.00	59.00	81.00	73.00	65.00	63.00	60.00	60.00	33.00
Long Term Debt	-0.2%	648	649	650	651	652	653	654	655	656	657	658	659	660	689	664
LT Debt, Current	25.0%	9.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00
LT Debt, Non Current	-0.2%	648	649	650	651	652	653	654	655	656	657	658	659	660	689	664
Shareholder's Equity	-13.5%	762	881	895	827	815	788	818	787	832	846	824	749	711	756	-
Retained Earnings	-1.8%	-1,457	-1,431	-1,393	-1,451	-1,448	-1,446	-1,404	-1,403	-1,415	-1,375	-1,357	-1,388	-1,390	-1,092	-1,096
Additional Paid-In Capital	-4.0%	2,219	2,313	2,288	2,279	2,263	2,235	2,223	2,190	2,247	2,222	2,182	2,138	2,102	1,849	9.00
Shares Outstanding	-0.6%	410	413	412	412	413	413	413	415	410	409	408	406	275	241	227
Float	-	-	-	424	-	-	-	472	-	-	-	2,300	-	-	-	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	-73.7%	16.00	60.00	30.00	32.00	32.00	34.00	51.00	30.00	50.00	49.00	35.00	45.00	15.00	33.00	38.00	46.00	-	-	-
Share Based Compensation	-11.8%	29.00	33.00	18.00	25.00	56.00	3.00	4.00	30.00	17.00	3.00	4.00	47.00	232	7.00	0.00	2.00	-	1.00	-
Cashflow From Investing	5.7%	-12.87	-13.65	-14.96	-14.29	1.00	-13.77	-163	-34.40	-9.26	-27.06	-132	-9.69	-9.81	-73.49	-4.91	-3.41	-	-	-
Cashflow From Financing	-816.4%	-125	-13.71	-13.99	-14.09	-4.79	-21.71	-2.33	-91.40	-11.46	-4.18	-0.86	-14.02	-111	992	-2.53	28.00	-	-	-
Buy Backs	909.1%	78.00	8.00	9.00	10.00	-	18.00	-	84.00	-	-	-	-	-	-	-	-	-	-	-

GDRX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Revenue	$ 750,265	$ 766,554	$ 745,424
Costs and operating expenses:
Cost of revenue, exclusive of depreciation and amortization presented separately below	66,925	65,079	46,716
Product development and technology	135,836	143,137	125,860
Sales and marketing	341,328	357,631	370,217
General and administrative	125,515	144,792	154,686
Depreciation and amortization	107,668	54,177	34,539
Total costs and operating expenses	777,272	764,816	732,018
Operating (loss) income	(27,007)	1,738	13,406
Other expense, net:
Other expense	(4,008)	0	0
Interest income	32,171	9,274	59
Interest expense	(56,728)	(34,243)	(23,642)
Total other expense, net	(28,565)	(24,969)	(23,583)
Loss before income taxes	(55,572)	(23,231)	(10,177)
Income tax benefit (expense)	46,704	(9,597)	(15,077)
Net loss	$ (8,868)	$ (32,828)	$ (25,254)
Loss per share:
Basic (in usd per share)	$ (0.02)	$ (0.08)	$ (0.06)
Diluted (in usd per share)	$ (0.02)	$ (0.08)	$ (0.06)
Weighted average shares used in computing loss per share:
Basic (in shares)	410,315	412,858	409,981
Diluted (in shares)	410,315	412,858	409,981
Cost of revenue
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 610	$ 359	$ 798
Product development and technology
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	30,096	35,190	35,090
Sales and marketing
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	20,311	21,036	20,645
General and administrative
Stock-based compensation included in costs and operating expenses:
Total stock-based compensation	$ 53,803	$ 63,649	$ 103,929

GDRX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 672,296	$ 757,165
Accounts receivable, net	143,608	117,141
Prepaid expenses and other current assets	56,886	45,380
Total current assets	872,790	919,686
Property and equipment, net	15,932	19,820
Goodwill	410,769	412,117
Intangible assets, net	60,898	119,865
Capitalized software, net	95,439	70,072
Operating lease right-of-use assets, net	29,929	35,906
Deferred tax assets, net	65,268	0
Other assets	37,775	27,165
Total assets	1,588,800	1,604,631
Current liabilities
Accounts payable	36,266	17,700
Accrued expenses and other current liabilities	71,329	47,523
Current portion of debt	8,787	7,029
Operating lease liabilities, current	6,177	4,068
Total current liabilities	122,559	76,320
Debt, net	647,703	651,796
Operating lease liabilities, net of current portion	48,403	54,131
Other liabilities	8,177	7,557
Total liabilities	826,842	789,804
Commitments and contingencies
Stockholders' equity
Preferred stock, $0.0001 par value; 50,000 shares authorized and zero shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; Class A: 2,000,000 shares authorized, 92,355 and 83,293 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively; and Class B: 1,000,000 shares authorized, 301,732 and 313,732 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	40	40
Additional paid-in capital	2,219,321	2,263,322
Accumulated deficit	(1,457,403)	(1,448,535)
Total stockholders' equity	761,958	814,827
Total liabilities and stockholders' equity	$ 1,588,800	$ 1,604,631

About GoodRx Holdings Inc

GoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.

WEBSITE	goodrx.com
INDUSTRY	Healthcare Plans
EMPLOYEES	952

GoodRx Holdings Inc Frequently Asked Questions

What is the ticker symbol for GoodRx Holdings Inc? What does GDRX stand for in stocks?

GDRX is the stock ticker symbol of GoodRx Holdings Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of GoodRx Holdings Inc (GDRX)?

As of Tue Apr 23 2024, market cap of GoodRx Holdings Inc is 2.86 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GDRX stock?

You can check GDRX's fair value in chart for subscribers.

What is the fair value of GDRX stock?

You can check GDRX's fair value in chart for subscribers. The fair value of GoodRx Holdings Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of GoodRx Holdings Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GDRX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is GoodRx Holdings Inc a good stock to buy?

The fair value guage provides a quick view whether GDRX is over valued or under valued. Whether GoodRx Holdings Inc is cheap or expensive depends on the assumptions which impact GoodRx Holdings Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GDRX.

What is GoodRx Holdings Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, GDRX's PE ratio (Price to Earnings) is -322.5 and Price to Sales (PS) ratio is 3.81. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GDRX PE ratio will change depending on the future growth rate expectations of investors.